Metastatic Castration-Resistant Prostate Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Surface Oncology, Regeneron Pharmaceuticals

Posted on
by

Metastatic Castration-Resistant Prostate Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Surface Oncology, Regeneron Pharmaceuticals
Metastatic Castration-Resistant Prostate Cancer Pipeline Insights
DelveInsight’s, “Metastatic Castration-Resistant Prostate Cancer Pipeline Insight, 2025,” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Metastatic Castration-Resistant Prostate Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.

Metastatic Castration-Resistant Prostate Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma, Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen

Metastatic Castration-Resistant Prostate Cancer Pipeline constitutes 75+ key companies continuously working towards developing 75+ Metastatic Castration-Resistant Prostate Cancer treatment therapies, analyzes DelveInsight.

Metastatic Castration-Resistant Prostate Cancer Overview:

Prostate cancer (PCa) is one of the most commonly diagnosed cancers globally and stands as the third leading cause of cancer-related deaths among men in the United States. In most cases, the disease is initially found in a localized stage and is treated with radical prostatectomy and/or radiation therapy, often followed by androgen deprivation therapy (ADT). However, depending on the tumor’s aggressiveness, some patients may develop castration-resistant prostate cancer (CRPC) within ten years. Formerly referred to as “hormone-refractory” or “androgen-independent” prostate cancer, CRPC continues to depend on androgen receptor (AR) signaling despite becoming unresponsive to standard hormone-suppressing treatments like ADT.

Request for a detailed insights report on Metastatic Castration-Resistant Prostate Cancer pipeline insights

“Metastatic Castration-Resistant Prostate Cancer Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Metastatic Castration-Resistant Prostate Cancer Therapeutics Market.

Key Takeaways from the Metastatic Castration-Resistant Prostate Cancer Pipeline Report

  • DelveInsight’s Metastatic Castration-Resistant Prostate Cancer pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Metastatic Castration-Resistant Prostate Cancer treatment.

  • In September 2024, Ipsen announced that the Phase III CONTACT-02 trial for Cabometyx® and atezolizumab in metastatic castration-resistant prostate cancer (mCRPC) showed a non-significant improvement in overall survival but successfully met the progression-free survival (PFS) endpoint.

  • Also in September 2024, Foundation Medicine received FDA approval for FoundationOne®CDx and Liquid CDx as companion diagnostics for Lynparza® in BRCA-mutated mCRPC.

  • In July 2024, the ARANOTE trial demonstrated that NUBEQA® plus ADT significantly improved radiological PFS in metastatic hormone-sensitive castrate-resistant prostate cancer (mHSPC).

  • In July 2024, the FDA granted fast-track designation to SYNC-T SV-102 for mCRPC.

  • In June 2024, Kangpu Biopharmaceuticals received FDA approval for a Phase II/III trial of KPG-121 combined with Abiraterone for mCRPC.

  • In May 2024, Fusion Pharmaceuticals launched the Phase 2 AlphaBreak trial of FPI-2265 in mCRPC patients.

  • In April 2024, Astellas Pharma obtained European approval for XTANDI™ in high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer (nmHSPC).

  • In April 2024, FibroGen reported positive Phase 1 trial results for FG-3246 in mCRPC.

  • Key Metastatic Castration-Resistant Prostate Cancer companies such as Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma, Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen, and others are evaluating new drugs for Metastatic Castration-Resistant Prostate Cancer to improve the treatment landscape.

  • Promising Metastatic Castration-Resistant Prostate Cancer pipeline therapies in various stages of development include SRF617, Rucaparib, HP518, and others.

Metastatic Castration-Resistant Prostate Cancer Pipeline Analysis

The report provides insights into:

  • The report provides detailed insights into the key companies that are developing therapies in the Metastatic Castration-Resistant Prostate Cancer Market.

  • The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Castration-Resistant Prostate Cancer treatment.

  • It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Metastatic Castration-Resistant Prostate Cancer market.

Download our free sample page report on Metastatic Castration-Resistant Prostate Cancer pipeline insights

Metastatic Castration-Resistant Prostate Cancer Emerging Drugs

  • SRF617: Surface Oncology

  • Rucaparib: Clovis Oncology

  • HP518: Hinova Pharmaceuticals

Metastatic Castration-Resistant Prostate Cancer Companies

Over 75 leading companies are actively engaged in developing therapies for metastatic castration-resistant prostate cancer (mCRPC). Clovis Oncology is among those with a drug candidate in the most advanced stage of development, currently in Phase III clinical trials.

DelveInsight’s report covers around 75+ products under different phases of clinical development like

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Metastatic Castration-Resistant Prostate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous

  • Subcutaneous

  • Oral

  • Intramuscular

Metastatic Castration-Resistant Prostate Cancer Products have been categorized under various Molecule types such as

  • Monoclonal antibody

  • Small molecule

  • Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Metastatic Castration-Resistant Prostate Cancer Therapies and Key Companies: Metastatic Castration-Resistant Prostate Cancer Clinical Trials and advancements

Metastatic Castration-Resistant Prostate Cancer Pipeline Therapeutic Assessment

• Metastatic Castration-Resistant Prostate Cancer Assessment by Product Type

• Metastatic Castration-Resistant Prostate Cancer By Stage

• Metastatic Castration-Resistant Prostate Cancer Assessment by Route of Administration

• Metastatic Castration-Resistant Prostate Cancer Assessment by Molecule Type

Download Metastatic Castration-Resistant Prostate Cancer Sample report to know in detail about the Metastatic Castration-Resistant Prostate Cancer treatment market @ Metastatic Castration-Resistant Prostate Cancer Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Metastatic Castration-Resistant Prostate Cancer Current Treatment Patterns

4. Metastatic Castration-Resistant Prostate Cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Metastatic Castration-Resistant Prostate Cancer Late-Stage Products (Phase-III)

7. Metastatic Castration-Resistant Prostate Cancer Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Metastatic Castration-Resistant Prostate Cancer Discontinued Products

13. Metastatic Castration-Resistant Prostate Cancer Product Profiles

14. Metastatic Castration-Resistant Prostate Cancer Key Companies

15. Metastatic Castration-Resistant Prostate Cancer Key Products

16. Dormant and Discontinued Products

17. Metastatic Castration-Resistant Prostate Cancer Unmet Needs

18. Metastatic Castration-Resistant Prostate Cancer Future Perspectives

19. Metastatic Castration-Resistant Prostate Cancer Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Metastatic Castration-Resistant Prostate Cancer Pipeline Reports Offerings

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/